peptide elongation factor 2 has been researched along with Malaria, Falciparum in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagchus, WM; Bezuidenhout, D; Dhingra, SK; Fidock, DA; Giddins, MJ; Khandelwal, A; Marquart, L; McCarthy, JS; Odedra, A; Oeuvray, C; Tappert, A; Webb, L; Webster, R; Yalkinoglu, Ö; Yin, X | 1 |
| Badolo, L; Dhingra, SK; Fidock, DA; Giddins, MJ; Greco, B; Gumpp, C; Jonat, B; Oeuvray, C; Rottmann, M; Spangenberg, T; Yin, X | 1 |
1 trial(s) available for peptide elongation factor 2 and Malaria, Falciparum
| Article | Year |
|---|---|
Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection stu
Topics: Adult; Antimalarials; Double-Blind Method; Female; Humans; Malaria, Falciparum; Male; Middle Aged; Peptide Elongation Factor 2; Plasmodium falciparum; Young Adult | 2021 |
1 other study(ies) available for peptide elongation factor 2 and Malaria, Falciparum
| Article | Year |
|---|---|
Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor.
Topics: Animals; Antimalarials; Drug Resistance; Drug Therapy, Combination; Hemeproteins; Malaria, Falciparum; Mice; Mice, SCID; Naphthyridines; Peptide Elongation Factor 2; Plasmodium falciparum; Quinolines | 2020 |